

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE

~~P~~ STATEMENT BY APPLICANT

APR 09 2007

(use as many sheets as necessary)

1

of

2

COMPLETE IF KNOWN

Application Number	10/500,972
---------------------------	------------

Filing Date	July 2, 2004
--------------------	--------------

First Named Inventor	Melissa Egbertson
-----------------------------	--------------------------

Group Art Unit	1626
----------------	------

Examiner Name	Chung, Susannah Lee
---------------	---------------------

Attorney Docket Number 21021YP

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

/Susannah Chung/

Date Considered

05/10/2007

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 8/24/2006

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			COMPLETE IF KNOWN		
			Application Number	10/500,972	
			Filing Date	July 2, 2004	
			First Named Inventor	Melissa Egbertson	
			Group Art Unit	1626	
			Examiner Name	Chung, Susannah Lee	
Sheet	2	of	2	Attorney Docket Number	21021YP

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
/S.C.	3	LaFemina, R. L., et al., "Requirement of Active Human Immunodeficiency Virus Type 1 Integrase Enzyme for Productive Infection of Human T-Lymphoid Cells", Journal of Virology, Vol. 66, No. 12, pp. 7414-7419 (1992)
	4	Hazuda, H. J., et al., "Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication Cells", Science, Vol. 287, pp. 646-650 (2000)
	5	Young, S. D., et al., "L-743,726 (DMP-266): A Novel, Highly Potent Nonnucleoside Inhibitor of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase", Antimicrobial Agents and Chemotherapy, Vol. 39, No. 12, pp. 2602-2605 (1995)
	6	Vacca, J. P., et al., "L-735,524: An Orally Bioavailable Human Immunodeficiency Virus Type 1 Protease Inhibitor", Proc. Natl. Acad. Sci. USA, Vol. 91, pp. 4096-4100 (1994)
	7	Fauci, A. S., et al., "NIH Conference. Acquired Immunodeficiency Syndrome: Epidemiologic, Clinical, Immunologic, and Therapeutic Considerations", Annals of Internal Medicine, Vol. 100, pp. 92-106 (1984)
	8	The Medical Letter on Drugs and Therapeutics, "Diagnostic Tests for HIV", Vol. 39, No. 1008, pp. 81-84 (1997)
	9	Dean, M., et al., "Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CCR5 Structural Gene", Science, Vol. 273, pp. 1856-1862 (1996)
	10	Mylonakis, E., et al., "Laboratory Testing for Infection with the Human Immunodeficiency Virus: Established and Novel Approaches", American Journal of Medicine, Vol. 109, pp. 568-576 (2000)
	11	Constantine, N. T., "Serologic Tests For The Retroviruses - Approaching A Decade Of Evolution", AIDS, Vol. 7, pp. 1-13 (1993)
✓	12	Mellors, J. W., et al., "Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection", Annals of Internal Medicine, Vol. 126, No. 12, pp. 946-954 (1997)

Examiner Signature	/Susannah Chung/	Date Considered	05/10/2007
--------------------	------------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 8/24/2006